针对肿瘤科普内容真伪难辨、大众对肿瘤早筛重视不足等痛点，京东健康与中国抗癌协会将推出肿瘤防 治科普行动；围绕医疗资源均衡可及、基层医院专科建设等需求，双方将推出肿瘤医生赋能计划；此 外，双方还将开展肿瘤康复技术产学研合作。 在肿瘤专科建设及专病防治方面，依然存在医疗资源分布不均、临床决策复杂、科研转化滞后、患者管 理低效等系统性挑战。 京东健康医疗及AI应用平台部负责人表示，京东健康依托京医千询大模型，全面加速"医检诊药"闭环， 打造AI京医专业服务智能体、专家医生智能体、RWD科研平台，以医疗级AI为目标，形成资源可及、 决策可依、科研可转化、患者可管理的智能肿瘤防治体系，为医生赋能、为患者服务、为行业提效。 数据显示，我国每年新发癌症病例数超400万例，近10年来，患者5年生存率从33.3%上升至43.7%，但 谈癌色变、无症状不做肿瘤筛查、治胜于防等认知误区仍然存在。 大会前一日，樊代明院士专程率团队到访京东总部，与京东集团SEC委员、京东健康CEO曹冬和相关业 务团队进行了深入交流。双方围绕"肿瘤整合防治工程（2025-2030）"的推进路径展开务实探讨，樊院 士对京东健康在推动肿瘤防治体系化、数字化 ...

Core Viewpoint - The launch of the "Integrated Cancer Prevention and Treatment Project (2025-2030)" by the China Anti-Cancer Association and JD Health aims to create a comprehensive system for cancer prevention, screening, diagnosis, treatment, and rehabilitation, integrating advanced technologies like AI into clinical practice [1][3][4] Group 1: Project Overview - The project focuses on building a full-process system of "prevention-screening-diagnosis-treatment-rehabilitation" to enhance the capabilities of doctors and improve patient experiences throughout the cancer care cycle [3][4] - The initiative addresses common misconceptions about cancer, such as the lack of screening and the belief that treatment is more important than prevention [3][4] Group 2: Collaboration and Partnerships - JD Health has signed collaborative agreements with several hospitals, including Guangzhou Medical University First Affiliated Hospital and Sun Yat-sen Memorial Hospital, to work on AI-specific cancer projects [3][4] - The project aims to promote the transformation of scientific research into practical applications in cancer treatment and rehabilitation [4] Group 3: Challenges and Solutions - The healthcare sector faces systemic challenges such as uneven distribution of medical resources, complex clinical decision-making, and inefficient patient management [5] - JD Health plans to leverage its AI capabilities to create an intelligent cancer prevention and treatment system that enhances resource accessibility and decision-making for healthcare professionals [5] Group 4: Future Directions - JD Health is committed to continuous collaboration with various partners to deepen the integration of AI and clinical practice, aiming to explore a "Chinese solution" for cancer prevention and treatment [5]

Core Viewpoint - JD Health and the China Anti-Cancer Association launched the "Integrated Cancer Prevention and Treatment Project (2025-2030)" to create a comprehensive system for cancer prevention, screening, diagnosis, treatment, and rehabilitation, integrating AI and other advanced technologies into clinical practice [1][3]. Group 1: Project Initiatives - The project aims to address issues such as the difficulty in discerning the authenticity of cancer-related information and the public's lack of emphasis on early cancer screening by launching a cancer prevention and treatment science popularization initiative [1][3]. - JD Health and the China Anti-Cancer Association will introduce a cancer doctor empowerment program to meet the needs for balanced access to medical resources and the development of specialized departments in grassroots hospitals [1][3]. - The collaboration will also focus on academic and industrial cooperation in cancer rehabilitation technology [1][3]. Group 2: AI Integration and Development - JD Health is leveraging the JD Medical Qianxun model to accelerate the "medical testing, diagnosis, and treatment" closed loop, aiming to create an intelligent cancer prevention and treatment system that is resource-accessible, decision-reliable, research-translatable, and patient-manageable [1][3]. - The JD Internet Hospital's oncology specialty has been fully upgraded, combining a team of authoritative experts from top-tier hospitals with AI technology to establish an integrated service system for screening, diagnosis, treatment, and follow-up [1][3]. - The oncology specialty currently includes over 30,000 authoritative experts from top-tier hospitals [1][3]. Group 3: Collaborative Research - JD Health signed cooperation agreements with Guangzhou Medical University First Affiliated Hospital, Sun Yat-sen Memorial Hospital of Sun Yat-sen University, and Peking University Cancer Hospital to focus on AI applications in areas such as gastrointestinal tumors, prostate cancer, and respiratory system diseases [2][4]. - The collaboration will explore innovative applications and advancements in AI for image recognition, dynamic monitoring of conditions, and assisted diagnosis and treatment [2][4].

Group 1 - The core point of the news is that southbound funds have significantly reduced their holdings in JD Health, with a total net reduction of 704.93 million shares over the last five trading days and 1,253.46 million shares over the last 20 trading days [1] - As of now, southbound funds hold 267 million shares of JD Health, which accounts for 8.32% of the company's total issued ordinary shares [1] Group 2 - JD Health is primarily an investment holding company that provides pharmaceutical and health products, internet medical health services, health management, and smart medical health solutions [2] - The company's business includes retail pharmacy and medical health services, with retail pharmacy operations conducted through self-operated and online platforms as well as instant retail channels [2] - Medical health services are mainly provided through internet hospitals and medical large models, and the company also offers online marketing services such as advertising [2]

Group 1 - The core viewpoint of the article highlights the approval of Novartis' innovative drug, Noreda® (Acrylamide Hydrochloride Tablets), as the first non-immunosuppressive therapy for IgA nephropathy in China, addressing a significant treatment gap in this area [1][3] - IgA nephropathy is prevalent among young adults in China, particularly those aged 20 to 30, with a high risk of progression to kidney failure if not effectively managed [1] - The drug is expected to be used in conjunction with existing standard treatments, providing new options for long-term disease management for patients [1][3] Group 2 - JD Health will leverage its robust pharmaceutical health service ecosystem to deepen its focus on chronic disease management, particularly in kidney diseases [1] - The collaboration with a leading global pharmaceutical company like Novartis aims to introduce cutting-edge therapeutic drugs and comprehensive digital health management solutions for patients [1][3] - JD Health's capabilities in supply chain fulfillment and professional pharmacist services will enhance the accessibility and precision of innovative drugs reaching patients nationwide [3]

Core Insights - Novartis has launched its innovative drug, Noreda (Acrylamide Hydrochloride Tablets), on JD Health, marking it as the first approved non-immunological therapy for adult patients with primary IgA nephropathy in China [1][2] - The drug is a highly selective endothelin A (ETA) receptor antagonist, filling a significant gap in non-hormonal basic treatments for this condition [2] Group 1 - Noreda is designed to reduce the risk of rapid disease progression in IgA nephropathy patients, which is prevalent among young adults aged 20 to 30 in China [1] - Clinical studies indicate that approximately 50% of IgA nephropathy patients with persistent proteinuria may progress to renal failure within 10 to 20 years if not effectively managed [1] - The collaboration between JD Health and Novartis aims to enhance the accessibility and precision of innovative treatments for patients nationwide [1][2] Group 2 - JD Health plans to deepen its focus on chronic disease management, particularly in kidney diseases, by leveraging its robust healthcare service ecosystem [2] - The introduction of Noreda is expected to provide new options for long-term disease management alongside existing standard treatments [2] - JD Health aims to offer comprehensive digital health management solutions for patients, improving the quality of life for those with kidney diseases and other chronic conditions [2]

Core Viewpoint - Novartis has launched its innovative drug, Noreida® (Acrylamide Hydrochloride Tablets), on JD Health, marking a significant advancement in the treatment of IgA nephropathy in adult patients in China [1][2]. Group 1: Product Launch and Significance - Noreida® is the first approved non-immunotherapy for reducing the risk of rapid disease progression in adult patients with IgA nephropathy in China [1]. - It is currently the only high-selective endothelin A (ETA) receptor antagonist for this indication in the country [1]. - The drug fills a gap in non-hormonal foundational treatments for this condition, providing a new option for clinicians to manage the disease alongside existing standard treatments [2]. Group 2: Market and Patient Impact - IgA nephropathy is a common primary glomerular disease prevalent among young adults in China, particularly those aged 20 to 30 [1]. - If not effectively controlled, approximately 50% of patients with persistent proteinuria may progress to renal failure within 10 to 20 years post-diagnosis, necessitating lifelong dialysis or kidney transplantation [1]. - JD Health aims to leverage its supply chain capabilities and professional pharmacist services to ensure that innovative drugs like Noreida® reach patients more quickly and effectively across the country [1]. Group 3: Future Directions - JD Health plans to deepen its collaboration with leading global pharmaceutical companies like Novartis to introduce cutting-edge treatment options and focus on comprehensive digital health management solutions for chronic diseases, including kidney diseases [2]. - This strategy aims to enhance the quality of life for patients with kidney diseases and a broader population suffering from chronic conditions [2].

Core Insights - The National Medical Products Administration announced a complete ban on the production of mercury thermometers and sphygmomanometers starting January 1, 2026, leading to a significant market response [1] - The transition from mercury-based devices has been planned since China joined the Minamata Convention on Mercury in 2017, with a clear roadmap for phasing out these products [1] - The sales of electronic thermometers and blood pressure monitors have surged, with electronic thermometer sales increasing over 100% year-on-year and electronic blood pressure monitors up by 50% [1] Market Trends - The search volume for thermometers on JD Health has significantly increased in the past week, indicating a shift in consumer behavior towards safer and smarter home monitoring solutions [1] - Among the alternatives to mercury thermometers, non-mercury glass thermometers, ear thermometers, and forehead thermometers have emerged as the three main categories [1] - Non-mercury glass thermometers cater to traditional users who prioritize safety and cost-effectiveness, while multifunctional ear thermometers are favored by families with infants for their quick measurement capabilities [1] - Forehead thermometers are preferred for their non-contact and high-efficiency features, appealing to users focused on convenience and public health scenarios [1] Product Innovations - Omron launched a new ear thermometer on JD Health, featuring a no-ear-cap design, 1-second measurement, and high fever alerts, quickly gaining market attention [2] - JD Health offers services such as 211 same-day delivery and a 180-day exchange policy for electronic thermometers, addressing consumer needs during peak flu seasons [2] - The policy-driven upgrade trend in health monitoring devices reflects an increase in public health awareness and indicates a shift towards more professional and intelligent home health monitoring solutions [2] - JD Health aims to leverage data insights, product supply, and service innovation to support the development of a more secure and intelligent family health management ecosystem [2]

Core Insights - The National Medical Products Administration announced a ban on the production of mercury thermometers and sphygmomanometers starting January 1, 2026, leading to a significant increase in demand for alternative health monitoring devices [1][4] - The market has seen a surge in electronic thermometer sales, with a year-on-year increase of over 100%, and electronic blood pressure monitors growing by 50% [1] - The transition away from mercury devices has been planned since China joined the Minamata Convention on Mercury in 2017, allowing for a gradual phase-out and providing consumers with ample time to adapt [1] Market Trends - The search volume for thermometers on JD Health has surged, indicating a shift towards safer and smarter home monitoring solutions [1] - Among the alternatives to mercury thermometers, non-mercury glass thermometers, ear thermometers, and forehead thermometers have emerged as the three main categories [1] - Non-mercury glass thermometers cater to traditional users who prioritize safety and cost-effectiveness, while multifunctional ear thermometers are favored by families with infants for their quick measurement capabilities [1] Product Launches and Services - Omron's new ear thermometer was launched on JD Health, featuring a no-ear-cap design, 1-second measurement, and high fever alerts, quickly gaining market attention [2] - JD Health offers various services for electronic thermometers, including same-day delivery and a 180-day exchange policy for PLUS members, addressing consumer needs during flu season [2] Industry Outlook - The policy-driven upgrade in health monitoring devices reflects an increase in public health awareness and indicates a trend towards professional and intelligent home health monitoring solutions [4] - JD Health is positioned as a key player in observing health consumption trends and aims to enhance the ecosystem of home health management through data insights and service innovations [4]

Group 1 - Zoetis launched its classic pet antibiotic, Synulox, exclusively on JD Health, aiming to enhance the accessibility and standardization of pet infection medications [1] - By the end of 2024, the number of urban dogs and cats in China is expected to exceed 120 million, with annual medical spending by pet owners increasing by 21.3% year-on-year [3] - Over 68% of pet owners prefer original drugs with international clinical validation, indicating a growing concern for the safety, efficacy, and traceability of medications [3] Group 2 - The "Pet Infection Center," co-founded by JD Health and Zoetis, focuses on educating pet owners about infectious diseases, which are among the most common health issues for pets [4] - The center will provide authoritative, convenient, and scientific health solutions, leveraging Zoetis's research and clinical experience alongside JD Health's digital service capabilities [5] - JD Health is committed to building a rational medication ecosystem for pets and promoting scientific pet care concepts, while continuing to collaborate with top global animal health companies [7]